Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100

Vaccine

Volumn 14, Issue 9, 1996, Pages 886-891

  Idänpään Heikkilä, Ilona ^a   Wahlstrom E ^a   Muttilainen, S ^a   Nurminen, M ^a   Kayhty H ^a   Sarvas, M ^a   Makela P H ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Adjuvants; Bacillus; Class 1 protein; Detergents; Immune response; Neisseria meningitidis; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; OUTER MEMBRANE PROTEIN; TRITON X 100; UNCLASSIFIED DRUG; ZWITTERGENT 314;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030174312     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00263-Z     Document Type: Article

References (23)

1. 1 Peltola, H. Meningococcal disease: still with us. Rev. Infect. Dis. 1983, 5, 71-91
2. 2 Wyle, F.A., Artenstein, M.S., Brandt, B.L. et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 1972, 126, 514-522
3. 3 Finne, J., Leinonen, M. and Mäkelä, P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, ii, 355-357
4. 4 Hitchcock, P. Unified nomenclature for pathogenic Neisseria species. Clin. Microbiol. Rev. 1989, 2, S64-S65
5. 5 McGuinness, B., Barlow, A.K., Clarke, I.N. et al. Deduced amino acid sequences of class 1 protein (PorA) from three strains of Neisseria meningitidis. Synthetic peptides define the epitopes responsible for serosubtype specificity. J. Exp. Med. 1990, 171, 1871-1882
6. 6 Barlow, A.K., Heckels, J.E. and Clarke, I.N. The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins. Molec. Microbiol. 1989, 3, 131-139
7. 7 Poolman, J.T., de Marie, S. and Zanen, H.C. Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infect. Immun. 1980, 30, 642-648
8. 8 Maiden, M.C.J., Suker, J., McKenna, A.J. et al. Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis. Molec. Microbiol. 1991, 5, 727-736
9. 9 Feavers, I.M., Heath, A.B., Bygraves, J.A. et al. Role of horizontal genetic exhange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis. Molec. Microbiol. 1992, 6, 489-495
10. 10 Saukkonen, K., Leinonen, M., Abdillahi, H. et al. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989, 7, 325-328
11. 11 Nurminen, M., Butcher, S., Idanpään-Heikkilä, I. et al. The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity. Molec. Microbiol. 1992, 6, 2499-2506
12. 12 Idanpään-Heikkilä, I., Muttilainen, S., Wahlström, E. et al. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine 1995, 13, 1501-1508
13. 13 Muttilainen, S., Idanpään-Heikkilä, I., Wahlström, E. et al. The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Microbial. Pathogenesis 1994, 18, 423-436
14. 14 James, L.T. and Heckels, J.E. An improved method for the isolation of the major protein of the gonococcal outer membrane in an antigenically reactive form. J. Immunol. Meth. 1981, 42, 223-228
15. 15 Blake, M.S. and Gotschlich, E.C. Purification and partial characterization of the major outer membrane protein of Neisseria gonorrhoeae. Infect. Immunity 1982, 36, 277-283
16. 16 Wedege, E., Bjune, G., Froholm, L.O. et al. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. Niph. Ann. 1991, 14, 183-186
17. 17 Mandrell, R.E. and Zollinger, W.D. Use of a zwitterionic detergent for the restoration of the antibody/binding capacity of electroblotted meningococcal outer membrane proteins. J. Immunol. Meth. 1984, 67, 1-11
18. 18 Helenius, A. and McCaglin, D.R. Methods in Enzymology 1st, Vol. LVI. 1979, 734-750. Academic Press, New York
19. 19 Helenius, A. and Simons, K. Solubilization of membranes by detergents. Biochim. Biophys. Acta 1975, 415, 29-79
20. 20 Mitchell, M.S., Kan-Mitchell, J., Kempf, R.A. et al. Active specific immunotherapy for melanoma: Phase I trial of allogenic lysates and a novel adjuvant. Cancer Res. 1988, 48, 5883-5893
21. 21 Gordon, M.D. Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine 1993, 11, 591-593
22. 22 Neuberger, M.S. and Rajewsky, K. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 1981, 11, 1012-1016
23. 23 Kenney, J.S., Hughes, B.W., Masada, M.P. et al. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 1989, 121, 157-166